SLC2A9 (solute carrier family 2 member 9)

2015-06-01  

Identity

HGNC
LOCATION
4p16.1
LOCUSID
ALIAS
GLUT9,GLUTX,UAQTL2,URATv1
FUSION GENES

Other Information

Locus ID:

NCBI: 56606
MIM: 606142
HGNC: 13446
Ensembl: ENSG00000109667

Variants:

dbSNP: 56606
ClinVar: 56606
TCGA: ENSG00000109667
COSMIC: SLC2A9

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000109667ENST00000264784Q9NRM0
ENSG00000109667ENST00000309065Q9NRM0
ENSG00000109667ENST00000506583Q9NRM0
ENSG00000109667ENST00000513129D6REK5

Expression (GTEx)

0
1
2
3
4
5
6

Pathways

PathwaySourceExternal ID
Transmembrane transport of small moleculesREACTOMER-HSA-382551
SLC-mediated transmembrane transportREACTOMER-HSA-425407
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsREACTOMER-HSA-425366
Facilitative Na+-independent glucose transportersREACTOMER-HSA-428790
Class II GLUTsREACTOMER-HSA-428776

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
381508922024Raised CK and acute kidney injury following intense exercise in three patients with a history of exercise intolerance due to homozygous mutations in SLC2A9.0
381508922024Raised CK and acute kidney injury following intense exercise in three patients with a history of exercise intolerance due to homozygous mutations in SLC2A9.0
367368752023The in-silico evaluation of important GLUT9 residue for uric acid transport based on renal hypouricemia type 2.0
371761612023Pathogenic Variants of SLC22A12 (URAT1) and SLC2A9 (GLUT9) in Spanish Patients with Renal Hypouricemia: Founder Effect of SLC2A9 Variant c.374C>T; p.(T125M).2
373085672023GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study.0
367368752023The in-silico evaluation of important GLUT9 residue for uric acid transport based on renal hypouricemia type 2.0
371761612023Pathogenic Variants of SLC22A12 (URAT1) and SLC2A9 (GLUT9) in Spanish Patients with Renal Hypouricemia: Founder Effect of SLC2A9 Variant c.374C>T; p.(T125M).2
373085672023GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study.0
352032842022Glucose Transporter 9 (GLUT9) Plays an Important Role in the Placental Uric Acid Transport System.4
360065482022The regulation effect of GLUT9/SLC2A9 on intrahepatic uric acid level and metabolic associated fatty liver disease.3
352032842022Glucose Transporter 9 (GLUT9) Plays an Important Role in the Placental Uric Acid Transport System.4
360065482022The regulation effect of GLUT9/SLC2A9 on intrahepatic uric acid level and metabolic associated fatty liver disease.3
327787632021Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects.6
328069752021The haplotype of SLC2A9_rs3733591, PKD2_rs2725220 and ABCG2_rs2231142 increases the hyperuricaemia risk and alcohol, chicken and processed meat intakes and smoking interact with its risk.7
347168632021The effects of hyperuricemia on endothelial cells are mediated via GLUT9 and the JAK2/STAT3 pathway.4

Citation

Dessen P

SLC2A9 (solute carrier family 2 member 9)

Atlas Genet Cytogenet Oncol Haematol. 2015-06-01

Online version: http://atlasgeneticsoncology.org/gene/55281/img/js/lib/all.min.js